Shenzhen Salubris Pharmaceuticals Co Ltd (002294) — Cash Flow Reinvestment Rate
Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has a Cash Flow Reinvestment Rate of 0.73x as of September 2025, reinvesting CN¥292.24 Million (capex CN¥292.24 Million ) from operating cash flow of CN¥400.70 Million. See Shenzhen Salubris Pharmaceuticals Co Ltd (002294) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Shenzhen Salubris Pharmaceuticals Co Ltd Cash Flow Reinvestment Rate (2006–2024)
Historical reinvestment intensity for Shenzhen Salubris Pharmaceuticals Co Ltd across 19 annual periods. For the full cash flow conversion analysis, see 002294 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
Year-by-year capital reinvestment analysis for Shenzhen Salubris Pharmaceuticals Co Ltd. See 002294 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.29x | CN¥1.53 Billion | CN¥1.19 Billion | CN¥624.81 Million | ▼ -45.2% |
| 2023 | 2.35x | CN¥2.04 Billion | CN¥869.79 Million | CN¥671.00 Million | ▲ +77.9% |
| 2022 | 1.32x | CN¥1.28 Billion | CN¥970.80 Million | CN¥598.96 Million | ▲ +171.4% |
| 2021 | 0.49x | CN¥576.03 Million | CN¥1.18 Billion | CN¥482.50 Million | ▼ -23.0% |
| 2020 | 0.63x | CN¥867.50 Million | CN¥1.37 Billion | CN¥642.47 Million | ▲ +39.8% |
| 2019 | 0.45x | CN¥680.11 Million | CN¥1.51 Billion | CN¥457.19 Million | ▼ -19.3% |
| 2018 | 0.56x | CN¥749.80 Million | CN¥1.34 Billion | CN¥332.87 Million | ▼ -33.3% |
| 2017 | 0.84x | CN¥1.22 Billion | CN¥1.46 Billion | CN¥331.67 Million | ▲ +55.1% |
| 2016 | 0.54x | CN¥775.06 Million | CN¥1.43 Billion | CN¥245.06 Million | ▲ +33.7% |
| 2015 | 0.40x | CN¥426.57 Million | CN¥1.06 Billion | CN¥235.57 Million | ▲ +97.7% |
| 2014 | 0.20x | CN¥200.65 Million | CN¥982.25 Million | CN¥200.65 Million | ▼ -68.0% |
| 2013 | 0.64x | CN¥427.20 Million | CN¥668.52 Million | CN¥427.20 Million | ▲ +16.2% |
| 2012 | 0.55x | CN¥286.75 Million | CN¥521.21 Million | CN¥286.75 Million | ▼ -40.7% |
| 2011 | 0.93x | CN¥252.60 Million | CN¥272.32 Million | CN¥252.60 Million | ▼ -22.5% |
| 2010 | 1.20x | CN¥223.48 Million | CN¥186.65 Million | CN¥223.48 Million | ▲ +18.5% |
| 2009 | 1.01x | CN¥135.68 Million | CN¥134.28 Million | CN¥135.68 Million | ▲ +28.0% |
| 2008 | 0.79x | CN¥61.48 Million | CN¥77.89 Million | CN¥61.48 Million | ▲ +203.8% |
| 2007 | 0.26x | CN¥13.71 Million | CN¥52.75 Million | CN¥13.71 Million | ▼ -67.9% |
| 2006 | 0.81x | CN¥9.71 Million | CN¥12.00 Million | CN¥9.71 Million | — |